Tag: Serranator
Cagent Vascular raises US$30 million series C financing
Cagent Vascular has announced a series C financing close in excess of US$30 million. US Venture Partners (USVP) led the round. Participation included new...
RECOIL study: Serranator demonstrates 49% less recoil than plain balloon angioplasty...
Cagent Vascular has announced the results of its below-the-knee (BTK) RECOIL study. This core lab-adjudicated Recoil analysis— the first of its kind, according to...
Study finds Serranator serration balloon safe and effective in pedal arteries
A recent study has concluded that the “novel” technique of serration angioplasty with the Serranator balloon (Cagent Vascular) for the treatment of chronic limb-threatening...
Cagent Vascular announces commercial launch of the Serranator above-the-knee product
Cagent Vascular has announced the expansion of its product offering to include larger balloons to treat superficial femoral and popliteal arteries in the above-the-knee...
Sectoral Asset Management makes US$9 million investment into Cagent Vascular
Cagent Vascular recently announced the investment of US$9 million by Sectoral Asset Management. Along with the investment, Marc-Andre Marcotte has joined the board of...
LINC 2021: PRELUDE-BTK results confirm Serranator device novel mechanism of action
Cagent Vascular announced the results of its PRELUDE-BTK study at LINC 2021 (The Leipzig Interventional Course; 25–29 January, online). The PRELUDE-BTK study was a...
Cagent Vascular appoints Brian Walsh as chairman of the board
Cagent Vascular, a developer of next-generation angioplasty balloons using proprietary serration technology, announces Brian Walsh to serve as chairman of the Board.
Brian Walsh...
Serranator PTA serration balloon catheter receives CE mark
Cagent Vascular has announced the issuance of its CE marking for the Serranator percutaneous transluminal angioplasty (PTA) serration balloon catheter. Cagent Vascular has also achieved...
Cagent Vascular completes enrolment of PRELUDE study using Serranator Alto device
Cagent Vascular has announced the completion of enrolment in the first-in-human PRELUDE study. The purpose of this prospective, single-arm, multicentre feasibility study is to...
Cagent Vascular announces FDA 510(k) clearance of Serranator Alto serration balloon...
Cagent Vascular has announced US Food and Drug Administration 510(k) clearance of its lead product, the Serranator Alto percutaneous transluminal angioplasty serration balloon catheter. The Serranator...
